Using new magnetic resonance technology MR spectroscopic imaging (MRSI) it is possible to “identify a metabolic signature for prostate cancer” that can effectively predict Gleason score without need for biopsy, according to researchers at Memorial Sloan-Kettering Cancer Center (MSK) in New York.
Hedvig Hricak, MD, PhD, chair of the department of radiology, discussed the new technology during a press conference at the 88th Scientific Assembly and Annual Meeting of the Radiological Society of North America. The study will be formally presented on Friday, Dec. 6. “Prostate cancer really requires ’boutique’ treatment tailored to each patient,” said Hricak.
“This noninvasive diagnostic technology allows us to do that.” The MRSI “gives a clear road map for treatment.” The MRSI tracks choline + creatine and citrate, Hricak said. “When the Gleason score is 6, choline is slightly elevated and citrate is low, but present. When the Gleason score is 8, choline is dramatically elevated and citrate is no longer present.
” Thus, by tracing the choline/citrate ratios “imaging can identify 72% of very aggressive prostate tumors those with Gleason scores of 7.5 or higher,” she said. “With that level of accuracy we can effectively plan treatment.”
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!